The material provided in this site is presented solely to improve public access to information about REVANCE. REVANCE will make reasonable efforts to include accurate and current information, wherever possible, but makes no warranties or representations, expressed or implied, as to its accuracy or completeness. REVANCE will not be liable for any damages, including but not limited to special or consequential damages, that result from the use of, or the inability to use, the material contained in this site. REVANCE may change the content of this site including the terms that govern the use of this site at any time without prior notice but does not assume any responsibility to update the information provided herein.
Some of the statements on this site are forward looking. Such statements are inherently subject to known and unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of REVANCE and affiliates to be materially different from those expected or anticipated in the forward-looking statements. REVANCE has no responsibility to update the forward-looking statements contained in this site to reflect events or circumstances occurring after the date of publication. You must not rely on this information for investment decisions.
Links to third-party sites
Links to third party sites are provided for convenience only, and the inclusion of any links does not imply endorsement by REVANCE. The linked sites are not under control of REVANCE, and REVANCE disclaims any liability for all third party information and the use of it.
Restrictions on use and submissions
The contents of this site are owned and controlled by REVANCE. No use of any of these may be made without the prior written consent of REVANCE, except for personal, non-commercial purposes. All submissions communicated to REVANCE through this site shall be and remain REVANCE’s property.
The glabella is the skin that sits between the eyebrows and above the nose. Facial wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors.
Revance will initially address one of the largest demands within the facial aesthetics category, glabellar (frown) lines.
Revance Clinical Program Update:
Product candidate DaxibotulinumtoxinA For Injection (RT002) has been evaluated in a Phase 2 head-to-head, active comparator study (BELMONT), completed last year in Canada, for the treatment of Glabellar Lines. Positive interim 6-month results were presented by Dr. Jean Carruthers, as a late-breaker at the 2015 AAD meeting. The company is preparing to initiate a Phase 3 program in the second half of 2016.
For the latest information regarding our clinical development programs, please see our public filings with the Securities and Exchange Commissions, as well as the press releases we issue, or visit www.clinicaltrials.gov
Anti-Aging: Facts, Figures & Trends
Use of botulinum toxin products for aesthetic and therapeutic indications represents an estimated $3.4 billion market globally.
Botulinum toxin procedures continue to drive the nonsurgical aesthetic market and have remained the #1 nonsurgical procedure since 2000.
Botulinum toxin injections (aesthetic) have seen a 5,407% increase in number of procedures from 1997-2014.*
A recent quantitative study of 80 community dermatologists and cosmetic surgeons revealed that RT002 injectable, if approved, would address an unmet need by offering a longer duration of effect. This same group voiced a significant likelihood to use RT002 injectable and make it their treatment of choice.**
* 2015 ASAPS Statistical data
** Revance. Data on file.
The glabella is the skin that sits between the eyebrows and above the nose.
Facial wrinkling is promoted by habitual facial expressions, aging, sun damage, smoking, poor hydration, and various other factors.
Aging theory suggests that wrinkles develop from incorrect repairs of injured elastic fibers and collagen fibers. Repeated extensions and compressions of the skin cause repeated injuries of extracellular fibers in derma. During the repairing process, some of the broken elastic fibers and collagen fibers are not regenerated and restored, but replaced by altered fibers.
Botulinum toxin treats glabellar (frown) lines by immobilizing the muscles that cause wrinkles.
Facts, Figures & Trends
Deeper muscles like those that form the glabellar (frown) lines may be better served by an injectable formulation like RT002.
RT002 injectable and RT001 topical are investigational product candidates. RT002 is currently undergoing clinical studies for both therapeutic and aesthetic indications. RT001 is in preclinical development.